Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
ARWR Arrowhead Pharmaceuticals, Inc. daily Stock Chart
ARWR [NASD]
Arrowhead Pharmaceuticals, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E73.87 EPS (ttm)0.54 Insider Own4.80% Shs Outstand101.11M Perf Week-6.30%
Market Cap4.02B Forward P/E- EPS next Y-0.44 Insider Trans-14.74% Shs Float98.88M Perf Month-16.50%
Income53.30M PEG10.08 EPS next Q-0.11 Inst Own67.00% Short Float10.09% Perf Quarter-17.50%
Sales163.60M P/S24.56 EPS this Y205.90% Inst Trans-1.21% Short Ratio4.21 Perf Half Y17.85%
Book/sh5.15 P/B7.72 EPS next Y-158.80% ROA13.20% Target Price68.57 Perf Year119.56%
Cash/sh4.96 P/C8.00 EPS next 5Y7.33% ROE18.20% 52W Range17.27 - 73.72 Perf YTD-37.35%
Dividend- P/FCF- EPS past 5Y20.60% ROI24.90% 52W High-48.12% Beta1.81
Dividend %- Quick Ratio6.90 Sales past 5Y295.20% Gross Margin- 52W Low121.44% ATR2.41
Employees134 Current Ratio6.90 Sales Q/Q-15.00% Oper. Margin27.80% RSI (14)25.65 Volatility4.01% 5.40%
OptionableYes Debt/Eq0.00 EPS Q/Q-121.20% Profit Margin32.60% Rel Volume0.38 Prev Close39.74
ShortableYes LT Debt/Eq0.00 EarningsFeb 05 AMC Payout0.00% Avg Volume2.37M Price38.24
Recom2.20 SMA20-9.96% SMA50-29.37% SMA2000.20% Volume575,548 Change-3.77%
Jan-21-20Initiated SVB Leerink Underperform $32
Dec-13-19Initiated Oppenheimer Perform
Nov-29-19Reiterated Chardan Capital Markets Buy $45 → $81
Nov-27-19Reiterated B. Riley FBR Buy $59 → $83
Nov-25-19Upgrade Robert W. Baird Neutral → Outperform $70
Oct-24-19Downgrade Robert W. Baird Outperform → Neutral $39
Oct-22-19Reiterated Chardan Capital Markets Buy $32 → $45
Oct-03-19Initiated Robert W. Baird Outperform $39
Sep-07-18Upgrade B. Riley FBR Neutral → Buy $18 → $19
Sep-06-18Reiterated Chardan Capital Markets Buy $17.50 → $24.50
Aug-08-18Reiterated Cantor Fitzgerald Overweight $13 → $18
Jul-02-18Reiterated Chardan Capital Markets Buy $9.50 → $16
May-09-18Upgrade Cantor Fitzgerald Neutral → Overweight $13
Mar-27-18Initiated Jefferies Buy $10
Feb-12-18Reiterated Cantor Fitzgerald Neutral $2 → $5
Feb-12-18Reiterated B. Riley FBR, Inc. Neutral $3 → $4
Jan-05-18Initiated B. Riley FBR, Inc. Neutral $3
Nov-27-17Upgrade Piper Jaffray Neutral → Overweight
Sep-18-17Upgrade William Blair Mkt Perform → Outperform
Nov-30-16Downgrade William Blair Outperform → Mkt Perform
Feb-13-20 04:47PM  Bragar Eagel & Squire is Investigating Certain Officers and Directors of Zuora, Arrowhead Pharmaceuticals, ResMed, and Covetrus and Encourages Investors to Contact the Firm GlobeNewswire
Feb-12-20 09:37PM  Edited Transcript of ARWR earnings conference call or presentation 5-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
Feb-07-20 09:36AM  Should First Trust Mid Cap Growth AlphaDEX ETF (FNY) Be on Your Investing Radar? Zacks
Feb-06-20 07:47AM  The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs Benzinga -5.99%
Feb-05-20 04:00PM  Arrowhead Reports Interim Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 Business Wire
04:00PM  Arrowhead Pharmaceuticals Reports Fiscal 2020 First Quarter Results Business Wire
07:43AM  The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data Benzinga
Feb-03-20 01:06PM  Arrowhead (ARWR) to Report Q1 Earnings: What's in the Cards? Zacks
Jan-24-20 05:31AM  Is Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) A Volatile Stock? Simply Wall St.
Jan-22-20 04:29PM  Will These Biotechs Rival A Top-Notch Stock In High Triglycerides? Investor's Business Daily
07:30AM  Arrowhead Pharmaceuticals to Webcast Fiscal 2020 First Quarter Results Business Wire
Jan-21-20 04:30PM  Why This Top-Notch Biotech Stock Just Plunged By Double Digits Investor's Business Daily -15.65%
Jan-16-20 03:55PM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Arrowhead Pharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Jan-11-20 08:00AM  These Four Stocks Are In Buy Range Before Key Healthcare Conference Investor's Business Daily
Jan-10-20 11:51AM  3 Biotech Stocks to Bank on for Buyouts in 2020 InvestorPlace
Jan-06-20 07:30AM  Arrowhead Pharmaceuticals Appoints James Hassard as Chief Commercial Officer Business Wire
Jan-02-20 08:00AM  Biotech Stocks Are On Fire Who's Leading The Profit Pack For 2020? Investor's Business Daily
Dec-27-19 06:06PM  Best Stocks 2019: Innovation, As Usual, Wins The Day Or Even The Year Investor's Business Daily
Dec-26-19 05:27AM  Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar? Zacks
Dec-24-19 10:00AM  What was the top stock of 2019? And should it be in your retirement account? MarketWatch
Dec-23-19 10:21AM  Arrowhead Pharma Investors Should Aim for Taking Profits TheStreet.com
08:00AM  Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)? Zacks
Dec-20-19 07:30AM  Arrowhead Pharmaceuticals Doses First Patient in AROAAT2002 Open Label Phase 2 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease Business Wire -6.19%
Dec-16-19 10:55PM  Edited Transcript of ARWR earnings conference call or presentation 25-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
04:15PM  Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) Business Wire
07:30AM  Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-HSD for Treatment of Alcohol and Nonalcohol Related Liver Disease Business Wire
Dec-13-19 06:12PM  Live Nation Entertainment, Zebra Technologies, STERIS Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 PR Newswire
07:30AM  Arrowhead Pharmaceuticals Appoints Marianne De Backer to Board of Directors Business Wire
Dec-11-19 03:46PM  Did Hedge Funds Drop The Ball On Arrowhead Research Corp (ARWR) ? Insider Monkey
07:30AM  Arrowhead Pharmaceuticals Files IND for Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma Business Wire
Dec-06-19 04:01PM  Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $266.8 Million Business Wire
Dec-04-19 06:00AM  Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock Business Wire
Dec-03-19 09:26AM  Where to Buy Booming Biotech ETFs Investopedia +8.42%
06:55AM  Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar? Zacks
Dec-02-19 04:48PM  This Highly Rated Biotech Company Just Tumbled 13% On A Public Offering Investor's Business Daily -13.26%
04:05PM  Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock Business Wire
02:57PM  7 Exciting Biotech Stocks to Buy Now InvestorPlace
Nov-29-19 01:23PM  This Biotech With 488% Growth In 2019 Just Gained A Price-Target Boost Investor's Business Daily +5.78%
09:52AM  Biotech Arrowhead Stocks Surge Will Continue, Analyst Says Barrons.com
Nov-28-19 08:07AM  Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)? Zacks
Nov-27-19 07:26AM  The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen Benzinga
04:55AM  Arrowhead Pharmaceuticals, Inc. Just Missed Earnings And Its EPS Looked Sad - But Analysts Have Updated Their Models Simply Wall St.
Nov-26-19 04:00PM  Arrowhead Pharmaceuticals to Participate in Upcoming December 2019 Conferences Business Wire +18.79%
Nov-25-19 04:00PM  Arrowhead Pharmaceuticals Reports Fiscal Year 2019 Results Business Wire +15.83%
10:27AM  Novartiss Deal for Medicines Company Is Good News for 2 More Stocks Barrons.com
Nov-18-19 09:32AM  Arrowhead Presents New Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at AHA Scientific Sessions 2019 Business Wire
Nov-15-19 07:30AM  Arrowhead Pharmaceuticals Announces Planned Management Transition Business Wire
Nov-13-19 02:12PM  Arrowhead Shares Are Still Alerting Big Buy Signals Investopedia +7.15%
Nov-11-19 07:30AM  Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Year End Results Business Wire
06:29AM  Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar? Zacks
Nov-08-19 04:13PM  Why It Could Soon Be Time To Take Profits In This Highflying Biotech Stock Investor's Business Daily +6.31%
08:00AM  Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data for Investigational Hepatitis B Regimens at The Liver Meeting® 2019 Business Wire
Nov-06-19 06:38AM  Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)? Zacks
Oct-31-19 12:15PM  Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ENaC at the North American Cystic Fibrosis Conference Business Wire
06:30AM  Dicerna ropes in Roche on gene-silencing deal worth up to $1.67B American City Business Journals
Oct-30-19 08:41AM  Best Growth Stocks for November 2019 Investopedia
Oct-26-19 07:51AM  The Arrowhead Pharmaceuticals (NASDAQ:ARWR) Share Price Is Up 557% And Shareholders Are Delighted Simply Wall St.
Oct-23-19 01:25PM  Hedge Funds Have Never Been More Bullish On Arrowhead Pharmaceuticals, Inc. (ARWR) Insider Monkey
Oct-18-19 04:38PM  Biotech Says It Hurdled A Genetic Barrier, But Shares Gave Up A Breakout Investor's Business Daily
11:10AM  Arrowhead Pharmaceuticals Is Flying Higher on the Charts TheStreet.com
07:30AM  Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of RNAi Therapeutics Business Wire
Oct-04-19 12:11PM  Medical stocks on the move: AbbVie, Arrowhead Pharmaceuticals and Zynex MarketWatch
Oct-02-19 04:15PM  Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics Business Wire
Sep-30-19 04:00PM  Arrowhead Pharmaceuticals to Participate in Upcoming October 2019 Conferences Business Wire
Sep-27-19 09:15AM  ARWR: Broad-Based Pipeline Progress. Three Pivotal Studies, Value-Inflection Opportunities In View. Zacks Small Cap Research
Sep-20-19 04:00PM  Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) Business Wire
10:19AM  Is Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Paid Enough Relative To Peers? Simply Wall St.
Sep-16-19 03:00AM  Arrowhead Pharmaceuticals Presents Initial Top-Line Clinical Data and Preclinical Data on RNAi Candidates ARO-APOC3 and ARO-ANG3 Business Wire
Sep-09-19 06:51AM  Should First Trust Small Cap Growth AlphaDEX Fund (FYC) Be on Your Investing Radar? Zacks -8.92%
Sep-08-19 07:28PM  Here's Why Arrowhead Pharmaceuticals Rose 17.6% in August Motley Fool
Aug-30-19 04:00PM  Arrowhead Pharmaceuticals to Participate in Upcoming September 2019 Conferences Business Wire
Aug-29-19 04:21PM  Why This Newly Profitable Biotech Stock Is Flirting With A Breakout Investor's Business Daily
11:02AM  Arrowhead Pharmaceuticals and three other stocks to watch MarketWatch
Aug-28-19 03:16PM  Is Arrowhead Pharmaceuticals Inc (ARWR)s Recently Published U.S. Patent Application A Blockbuster? Insider Monkey
07:30AM  Arrowhead Collaborator Janssen Begins REEF-1 Phase 2b Combination Study in Patients with Chronic Hepatitis B Infection Business Wire
Aug-21-19 12:37PM  Arrowhead Pharmaceuticals: Buy at the High? Motley Fool
Aug-19-19 11:44AM  Arrowhead Pharma Shares Quietly See Big Buy Demand Investopedia +8.11%
Aug-15-19 11:59AM  Could The Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Ownership Structure Tell Us Something Useful? Simply Wall St.
09:00AM  BioBoyScouts Online Biotech Valuation Calculators Help Small Investors See Value in Arrowhead Pharmaceuticals (ARWR) Insider Monkey
Aug-12-19 06:10AM  Edited Transcript of ARWR earnings conference call or presentation 5-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-08-19 07:30AM  Arrowhead Pharmaceuticals Doses First Patient in SEQUOIA Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease Business Wire
Aug-06-19 06:00AM  What You'll Want to Know About Arrowhead Pharmaceuticals' Q3 Update Motley Fool
Aug-05-19 11:23PM  Arrowhead Research Corp (ARWR) Q3 2019 Earnings Call Transcript Motley Fool -6.46%
04:00PM  Arrowhead Pharmaceuticals Reports Fiscal 2019 Third Quarter Results Business Wire
Jul-24-19 07:30AM  Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Third Quarter Results Business Wire
Jul-16-19 04:00PM  Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-ANG3 Business Wire
Jul-10-19 07:27AM  How Does Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Affect Your Portfolio Volatility? Simply Wall St.
Jul-08-19 07:30AM  Arrowhead Pharmaceuticals to Participate in Roth RNA Revolution Conference Business Wire
Jun-28-19 04:31PM  Highly Rated Biotech Downgraded After Breaking Out And Running 39% Investor's Business Daily -8.05%
07:32AM  The Daily Biotech Pulse: Chiasma To Join R3K Index, EU Rejects Amgen's Osteoporosis Drug Application, Karuna IPO Benzinga
06:45AM  Arrowhead Pharma Heads Down Midday After Downgrade Investing.com
Jun-27-19 07:30AM  Arrowhead Pharmaceuticals Receives Fast Track Designation for ARO-AAT for Treatment of Alpha-1 Liver Disease Business Wire
Jun-24-19 01:38PM  Hedge Funds Have Never Been This Bullish On Arrowhead Pharmaceuticals, Inc. (ARWR) Insider Monkey
Jun-21-19 06:45PM  Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) Business Wire
07:30AM  Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-APOC3 Business Wire
Jun-14-19 02:59PM  7 Top-Rated Biotech Stocks to Invest In Today InvestorPlace
Jun-12-19 03:32PM  Edited Transcript of ARWR earnings conference call or presentation 12-Dec-17 9:30pm GMT Thomson Reuters StreetEvents
Jun-11-19 03:44PM  Edited Transcript of ARWR earnings conference call or presentation 8-May-19 8:30pm GMT Thomson Reuters StreetEvents
Jun-10-19 10:02AM  Read This Before Judging Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) ROE Simply Wall St.
06:30AM  Here's Why Arrowhead Pharmaceuticals Surged 31.9% in May Motley Fool
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD for treating liver diseases; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a third-generation subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; AMG 890 to reduce production of apolipoprotein A; and ARO-AMG1 for treating undisclosed genetically-validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop RNAi therapeutics. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Myszkowski Kenneth AllenChief Financial OfficerJan 21Option Exercise5.1933,351173,092424,536Jan 23 06:15 PM
Myszkowski Kenneth AllenChief Financial OfficerJan 21Sale49.4440,3131,992,925384,223Jan 23 06:15 PM
GIVEN BRUCE DChief Operating OfficerJan 06Sale60.1335,6132,141,285858,993Jan 08 06:35 PM
O'Brien PatrickGeneral CounselJan 06Sale60.1214,625879,261258,375Jan 08 06:33 PM
Myszkowski Kenneth AllenChief Financial OfficerJan 06Sale60.1120,0001,202,201391,185Jan 08 06:31 PM
Anzalone Christopher RichardChief Executive OfficerDec 24Sale63.5083,3335,291,6461,805,237Dec 27 04:54 PM
Anzalone Christopher RichardChief Executive OfficerDec 13Sale66.7383,3335,560,4891,888,570Dec 13 06:35 PM
Anzalone Christopher RichardChief Executive OfficerDec 12Sale67.50100,0006,749,6301,971,903Dec 13 06:35 PM
Anzalone Christopher RichardChief Executive OfficerDec 03Sale61.5812,033740,9522,071,903Dec 04 06:48 PM
Anzalone Christopher RichardChief Executive OfficerDec 02Sale69.1537,9672,625,5702,083,936Dec 04 06:48 PM
Myszkowski Kenneth AllenChief Financial OfficerNov 05Option Exercise5.1912,64965,648326,185Nov 07 06:45 PM
Myszkowski Kenneth AllenChief Financial OfficerNov 01Option Exercise7.7537,884293,601351,420Nov 01 07:32 PM
Myszkowski Kenneth AllenChief Financial OfficerNov 01Sale40.8537,8841,547,378313,536Nov 01 07:32 PM
Anzalone Christopher RichardChief Executive OfficerOct 10Option Exercise5.2056,325292,8902,178,228Oct 11 07:31 PM
Anzalone Christopher RichardChief Executive OfficerOct 10Sale31.8356,3251,792,8252,121,903Oct 11 07:31 PM
Anzalone Christopher RichardChief Executive OfficerSep 25Sale28.2520,000565,0002,121,903Sep 27 09:16 PM
Anzalone Christopher RichardChief Executive OfficerSep 24Option Exercise5.1066,645339,8902,208,548Sep 24 09:12 PM
Anzalone Christopher RichardChief Executive OfficerSep 24Sale28.2066,6451,879,2402,141,903Sep 24 09:12 PM
Anzalone Christopher RichardChief Executive OfficerSep 23Option Exercise5.1041,755212,9512,183,658Sep 24 09:12 PM
Anzalone Christopher RichardChief Executive OfficerSep 23Sale29.0441,7551,212,5652,141,903Sep 24 09:12 PM
Anzalone Christopher RichardChief Executive OfficerSep 20Option Exercise5.104,25021,6752,146,153Sep 24 09:12 PM
Anzalone Christopher RichardChief Executive OfficerSep 20Sale29.004,250123,2502,141,903Sep 24 09:12 PM
PERRY MICHAEL SDirectorSep 11Sale30.0085,0002,550,00036,000Sep 11 08:09 PM
PERRY MICHAEL SDirectorSep 09Sale28.90100,0002,890,000121,000Sep 11 08:09 PM
Ferrari MauroDirectorJun 26Sale27.6117,756490,2431,900Jun 28 07:19 PM
Myszkowski Kenneth AllenChief Financial OfficerMay 31Option Exercise4.9435,000172,800313,536Jun 03 06:12 PM
O'Brien PatrickGeneral CounselMay 28Sale24.8830,000746,400203,000May 29 07:01 PM
Anzalone Christopher RichardChief Executive OfficerMay 24Option Exercise2.1349,448105,1102,141,903May 29 06:57 PM
Myszkowski Kenneth AllenChief Financial OfficerMay 21Sale22.0027,071595,562278,536May 22 05:44 PM
Anzalone Christopher RichardChief Executive OfficerApr 03Sale19.3050,000965,0002,092,455Apr 05 06:57 PM
GIVEN BRUCE DChief Operating OfficerMar 01Option Exercise2.0142,50085,425687,106Mar 01 08:42 PM
GIVEN BRUCE DChief Operating OfficerMar 01Sale19.9942,500849,575644,606Mar 01 08:42 PM
GIVEN DOUGLAS BDirectorFeb 26Option Exercise3.9265,000254,570240,130Feb 26 07:32 PM
GIVEN DOUGLAS BDirectorFeb 26Sale19.2565,0001,251,250175,130Feb 26 07:32 PM
GIVEN BRUCE DChief Operating OfficerFeb 25Option Exercise2.0142,50085,425687,106Feb 27 07:08 PM
GIVEN BRUCE DChief Operating OfficerFeb 25Sale18.9842,500806,650644,606Feb 27 07:08 PM
GIVEN DOUGLAS BDirectorFeb 22Sale18.053,00054,150175,130Feb 26 07:32 PM
open in yahoo | open in reuters | open in google